Pixium’s Prima sub-retinal wireless implant continues to advance through human feasibility trials. The EU study recently reached full enrolment and a US study is slated to start implantations in Q318. Using a risk-adjusted NPV model, we obtain a pipeline rNPV of €90.6m, vs €77.4m previously.
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.